Reading · Silverwood Weekly Healthcare Market Update

Strategy | Financing | Macro & Markets

Share Silverwood Weekly Healthcare Market Update

Private Placement / Financing Transactions

Celea Therapeutics: The company raised $180 million of venture funding from Leaps by Bayer, PureTech Health and RA Capital Management on July 2, 2026. The company is a developer of therapies for chronic respiratory diseases.SonoThera: The company raised $125 million of Series B venture funding in a deal led by Vida Ventures (Los Angeles) on June 29, 2026. The company is a developer of ultrasound-mediated nonviral gene therapies for genetic diseases.Flare Therapeutics: The company raised $85 million of Series C venture funding in a deal led by Third Rock Ventures and Nextech Invest on June 30, 2026, putting the company’s pre-money valuation at $118.4 million. The company is a developer of small-molecule precision medicines targeting transcription factors in cancer.Integral: The company raised $25 million of venture funding from LiveRamp Ventures, WS Investments and LifeX Ventures on July 2, 2026. The company is a provider of healthcare data intelligence software for clinical and operational analytics.Myrtelle: The company raised venture funding in the form of convertible debt from undisclosed investors on July 2, 2026. The company is a clinical-stage developer of gene therapies for rare neurological diseases.Reprise Biomedical: The company raised venture funding from undisclosed investors on July 1, 2026. The company is a developer of biologic implants for soft tissue repair and regenerative medicine.Pictor: The company raised $7.5 million of venture funding in the form of convertible debt from undisclosed investors on June 30, 2026. The company is a developer of multiplex proteomics technology for biomarker detection and clinical diagnostics.Smartbax: The company raised EUR 6.3 million of venture funding from High-Tech Gründerfonds, Boehringer Ingelheim Venture Fund and Bayern Kapital on June 30, 2026. The company is a developer of multi-target antibacterial therapies for drug-resistant bacterial infections.VedaPointe: The company raised $4 million of venture funding from Early Light Ventures and other undisclosed investors on June 30, 2026. The company is a provider of healthcare communication software for patient engagement.DropGenie: The company raised venture funding in a deal led by Skeleton Key Management on June 30, 2026. The company is a developer of microfluidics systems for automating synthetic biology and laboratory workflows.Ameratat: The company raised an undisclosed amount of venture funding from Future Tech Ventures in July 2026. The company is a developer of AI software for real-time colorectal cancer detection during colonoscopy.Archean Sciences: The company raised an undisclosed amount of venture funding from Origin Ventures Group in July 2026. The company is a developer of autonomous brain-on-a-chip systems for neurological drug discovery.Clearmind Biomedical: The company raised an undisclosed amount of venture funding from Bailey Biofund in July 2026. The company is a developer of micro-invasive neurosurgical visualization technology for intracranial procedures.Diabetes Free: The company raised an undisclosed amount of venture funding from Candy Ventures in July 2026. The company is a biotechnology developer of antigen-specific immune tolerance therapies for autoimmune diseases, including type 1 diabetes.Everi Labs: The company raised an undisclosed amount of venture funding from Node Ventures, Inception Fund and Norrsken Evolve on June 29, 2026. The company is a developer of AI software that automates clinical documentation for orthotics and prosthetics providers.Lumos: The company raised an undisclosed amount of venture funding from Next Play Ventures in July 2026. The company is a developer of light therapy glasses for circadian rhythm, sleep and daytime alertness.Momentum Life Sciences: The company received an undisclosed amount of development capital from Parthenon Capital Partners on July 1, 2026. The company is a provider of commercialization and patient engagement services for life sciences companies.PBR Life Sciences: The company raised an undisclosed amount of venture funding from Impact Foundation in July 2026. The company is a provider of real-world healthcare data and analytics for life sciences companies.

M&A Transactions

Aura Cacia / Country Life: Country Life, a portfolio company of Lion Equity Partners, acquired Aura Cacia, a division of Frontier Co-op, on July 7, 2026. Aura Cacia is a leading essential oils, skincare and aromatherapy brand offering essential oils, skin care oils, diffusers, mists, bath products and botanical wellness products. Silverwood Partners initiated the transaction and acted as exclusive financial advisor to Frontier Co-op and Aura Cacia.

Theravance Biopharma / Zymeworks:

The company reached a definitive agreement to be acquired by Zymeworks for $929 million on June 29, 2026. The company is a developer of medicines for respiratory and other serious diseases.Kartos Therapeutics / Ipsen: The company reached a definitive agreement to be acquired by Ipsen for up to $1.8 billion on June 29, 2026. The company is a clinical-stage developer of targeted therapies for hematologic cancers.Naveris / CareDx: The company was acquired by CareDx for up to $260 million on July 1, 2026. The company is a developer of blood-based molecular diagnostics for HPV-driven cancers.Iovera / Zimmer Biomet: The company reached a definitive agreement to be acquired by Zimmer Biomet for $140 million on June 30, 2026. The company is a developer of cryoneurolysis systems for non-opioid pain management.Thymmune / United Therapeutics: The company was acquired by United Therapeutics for up to $300 million on July 2, 2026. The company is a developer of thymic cell therapies for immune system restoration.Aptose Biosciences / Hanmi Pharm: The company was acquired by Hanmi Pharm for CAD 57.5 million on June 30, 2026. The company is a developer of clinical-stage targeted therapies for hematologic cancers.eTheRNA / Valerio Therapeutics: The company reached a definitive agreement to be acquired by Valerio Therapeutics for $30 million on July 1, 2026. The company is a developer of mRNA immunotherapies and therapeutic vaccines.Andone Pharmaceuticals / Sterimax: The company was acquired by Sterimax for an undisclosed amount on June 30, 2026. The company is a manufacturer of pharmaceutical products and medical devices.Beacon Intelligence / Ampersand Capital Partners: The company, a subsidiary of Hanson Wade, was acquired by Corten Capital and Ampersand Capital Partners through an LBO on June 30, 2026 for an undisclosed amount. The company is a provider of drug development databases and competitive intelligence for the biopharmaceutical industry.Cortigent / Clearone: The company reached a definitive agreement to acquire Clearone through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker symbol CRGT on July 02, 2026. The company is a developer of implantable neurostimulation systems for restoring sensory and motor function.Simbec-Orion / Caidya: The company was acquired by Caidya, via its financial sponsor Rubicon Founders, through an LBO on June 30, 2026 for an undisclosed amount. The company is a contract research organization providing clinical development services for biopharmaceutical companies.T.G.Medical / Medikit: The company was acquired by Medikit for an undisclosed amount on July 3, 2026. The company is a developer of endovascular medical devices for neurovascular and cerebrovascular procedures.Talawar Therapeutics / JATT II Acquisition: The company reached a definitive agreement to acquire JATT II Acquisition through a reverse merger, resulting in the combined entity trading on the Nasdaq Capital Market under the ticker symbol TLWR on June 29, 2026. The company is a developer of bispecific antibody therapies for inflammatory and immune-mediated diseases.UniD Manufacturing / Besins Healthcare: The company was acquired by Besins Healthcare for an undisclosed amount on July 2, 2026. The company is a developer of implantable drug delivery technologies for sustained release of pharmaceutical products.

Source: Pitchbook Data, Inc.
Connect on LinkedIn with Jonathan Hodson-Walker

No posts

Healthcare Private Placement and M&A Transactions Review

Comments